文献速递胸部肿瘤放疗

早期肺癌立体定向体部放疗中肿瘤细胞气道播散与治疗结局的关联

Association between tumor cell in air space and treatment outcomes in early-stage lung cancer treated with stereotactic body radiation therapy.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-05-17

回顾性分析68例接受立体定向体部放疗的早期肺癌患者,评估肿瘤细胞气道播散(TCIAS)对治疗结局的影响。中位随访24.3个月,TCIAS阳性是区域失败、远处失败和无进展生存的显著不良因素,但对局部进展和总生存无显著影响。

要点

  • TCIAS阳性与区域失败(HR 4.10)、远处失败(HR 2.61)和无进展生存(HR 2.36)显著相关。
  • TCIAS阳性对局部进展和总生存无显著影响。
  • TCIAS状态可能有助于预测早期肺癌立体定向体部放疗的结局。

核心结论

  • TCIAS阳性是立体定向体部放疗后区域失败和远处失败的不良因素。
  • TCIAS状态可能有助于预测早期肺癌立体定向体部放疗的治疗结局。

研究设计与样本

  • 回顾性分析68例接受立体定向体部放疗的早期肺癌患者数据。
  • 采用单因素和多因素分析评估TCIAS状态对局部进展无失败、区域无失败、远处无失败、无进展生存和总生存率的影响。
  • 中位随访时间为24.3个月。

主要发现

  • TCIAS阳性/阴性患者的2年局部进展无失败率分别为81.4%/91.1%。
  • TCIAS阳性/阴性患者的2年区域无失败率分别为73.7%/96.2%。
  • TCIAS阳性/阴性患者的2年远处无失败率分别为55.9%/75.3%。
  • TCIAS阳性/阴性患者的2年无进展生存率分别为55.0%/84.6%。
  • TCIAS阳性/阴性患者的2年总生存率分别为67.8%/92.2%。

关键数值与推荐

  • 多因素分析显示TCIAS阳性是区域无失败的显著不良因素(HR 4.10;95%CI 1.04-16.16,p=0.04)。
  • 多因素分析显示TCIAS阳性是远处无失败的显著不良因素(HR 2.61;95%CI 1.03-6.57,p=0.04)。
  • 多因素分析显示TCIAS阳性是无进展生存的显著不良因素(HR 2.36;95%CI 1.05-5.30,p=0.04)。
  • TCIAS阳性对局部进展无失败和总生存无显著影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Spread-through air space (STAS) is an unfavorable factor in patients with lung cancer treated with surgery. However, the relationship between the treatment outcomes of stereotactic body radiation therapy (SBRT) for lung cancer and STAS has not been adequately investigated. This study aimed to evaluate the impact of tumor cells in the air space (TCIAS), which show a STAS burden, on treatment outcomes in patients with early-stage lung cancer treated with SBRT. MATERIALS AND METHODS: Data of patients who underwent SBRT for early-stage lung cancer treated with SBRT were retrospectively reviewed. The influence of the TCIAS status on local progression-free (LPF), regional failure-free (RFF), distant failure-free (DFF), progression-free survival (PFS), and overall survival (OS) rates was assessed using univariate and multivariate analyses. RESULTS: Overall, 68 patients were included. The median follow-up time was 24.3 months. For patients positive/negative for TCIAS, the 2-year LPF, RFF, DFF, PFS, and OS rates were 81.4 %/91.1 %, 73.7 %/96.2 %, 55.9 %/75.3 %, 55.0 %/84.6 %, and 67.8 %/92.2 %, respectively. In the multivariate analysis, TCIAS-positive was a significant unfavorable factor for RFF (hazard ratio [HR]: 4.10; 95 % confidence interval [CI]: 1.04-16.16, p = 0.04), DFF (HR: 2.61, 95 % CI: 1.03-6.57, p = 0.04), and PFS (HR: 2.36; 95 % CI: 1.05-5.30, p = 0.04). By contrast, TCIAS-positive was not a significant risk factor for LPF and OS. CONCLUSION: TCIAS-positive is an unfavorable factor for regional and distant failure after SBRT. TCIAS status may be useful in predicting the treatment outcome of SBRT for early-stage lung cancer.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Makita K, Hamamoto Y, Kanzaki H, et al. Association between tumor cell in air space and treatment outcomes in early-stage lung cancer treated with stereotactic body radiation therapy. Clin Transl Radiat Oncol. 2024. PMID: 38783905. doi:10.1016/j.ctro.2024.100795

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。